Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075208 | 0.86 | GAA (0.54) | CES2PDE2AGAAMAPTKDM4E | |
| SCHEMBL24450665 | 0.83 | MEN1 (0.47) | CES2MAPTKDM4EHPGDALDH1A1 | |
| SCHEMBL5898534 | 0.83 | CES2 (0.66) | CES2MAPTKDM4EHPGDALDH1A1 | |
| SCHEMBL3916517 | 0.83 | PTPN1 (0.56) | CES2DDR1PDE2AGAAMRGPRX4 | |
| SCHEMBL27920621 | 0.81 | KDM4E (0.51) | CES2MAPTKDM4EHPGDALDH1A1 | |
| SCHEMBL27643680 | 0.81 | JAK2 (0.50) | CES2PDE2AMRGPRX4MAPTKDM4E | |
| SCHEMBL28233849 | 0.81 | CES2 (0.46) | CES2PDE2AMAPTKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL15732663 | 0.81 | CES2 (0.46) | CES2DDR1GAAMRGPRX4KDM4E | |
| SCHEMBL14054107 | 0.81 | CES2 (0.49) | CES2GAAMAPTKDM4EHPGD | |
| SCHEMBL2645532 | 0.81 | NPSR1 (0.45) | CES2DDR1GAAMRGPRX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| US-20130177529-A1 | Pyrazole Compounds | VIVOQUEST, INC. | 2013-07-11 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101679439-A | P70S 6 kinase inhibitors | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| CN-100395234-C | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| CN-101012193-A | Novel CB 1 receptour inverse agonists | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | CN | disclosed |
| CN-1735593-A | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| CN-1326457-A | 4-aminopyrrolopyrimidines as kinase inhibitors | BASF AG (DE) | 2001-12-12 | — | — | CN | disclosed |
| CN-1176101-A | N -(4 -aryl -thiazol -2 -yl) -sulphonamide derivatives and their use | HOFFMANN LA ROCHE (CH) | 1998-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177529-A1 | Pyrazole Compounds | MAVS, EIF2AK2, ZC3HAV1 | CES2 865/4885DDR1 4604/4885PDE2A 2054/4885 |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | CES2 4840/4885DDR1 2418/4885PDE2A 1727/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | CES2 3644/4885DDR1 2681/4885PDE2A 3489/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | CES2 3644/4885DDR1 2681/4885PDE2A 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.